MedTrace Logo

Clinical Evaluation of Patients With X-linked Retinoschisis

NCT02331173 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2017-11-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate subjects with X-linked retinoschisis in a clinical setting to collect data on disease progression.

Conditions

  • X-linked Retinoschisis
  • XLRS

Interventions

DRUG

Dorzolamide 2% TID or brinzolamide 1% TID

Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows: * Topical dorzolamide 2% three times per day * Topical brinzolamide 1% three times per day

Sponsors & Collaborators

  • Foundation Fighting Blindness

    collaborator OTHER

  • Beacon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Matt Feinsod, MD · Applied Genetics Technologies Corporation

Eligibility

Min Age
7 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02331173 on ClinicalTrials.gov